<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Capricor Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/capricor-therapeutics-inc</link>
<description>Latest news and press releases for Capricor Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/capricor-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835520578dffbe2df0e7dde.webp</url>
<title>Capricor Therapeutics Inc</title>
<link>https://6ix.com/company/capricor-therapeutics-inc</link>
</image>
<item>
<title>Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-presentation-of-hope-3-phase-3-results-at-the-american-academy-of-neurology-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-presentation-of-hope-3-phase-3-results-at-the-american-academy-of-neurology-2026-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Illinois. The data were presented by Dr. Aravindhan Veerapandiyan, Associate Professor and Director of th</description>
</item>
<item>
<title>Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/early-warning-press-release-frank-guillemette-announces-completion-of-acquisition-of-common-shares-of-caprock-mining-corp-1</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/early-warning-press-release-frank-guillemette-announces-completion-of-acquisition-of-common-shares-of-caprock-mining-corp-1</guid>
<pubDate>Mon, 23 Mar 2026 14:50:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Frank Guillemette (the "Acquiror ") announces that, on March 18, 2026, he acquired an aggregate of 957,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $105,476.97 CAD (the "Acquisition").Immediately prior to the Acquisition, the Acquiror held 11,043,366 common shares and 4,633,333 common share purchase...</description>
</item>
<item>
<title>Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
<description>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefitsSan Diego GMP manufacturing facility operational to support potential commercial launchCapricor uplisted to the Nasdaq Global Select MarketCash balance of approximately $318</description>
</item>
<item>
<title>Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-hope-3-data-at-the-2026-mda-conference-demonstrating-significant-functional-benefits-of-deramiocel-for-duchenne-muscular-dystrophy-24</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-hope-3-data-at-the-2026-mda-conference-demonstrating-significant-functional-benefits-of-deramiocel-for-duchenne-muscular-dystrophy-24</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline</description>
</item>
<item>
<title>Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by</description>
</item>
<item>
<title>Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-update-on-march-12</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-update-on-march-12</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a</description>
</item>
<item>
<title>Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-presentation-at-2026-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-late-breaking-presentation-at-2026-mda-clinical-and-scientific-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR)</description>
</item>
<item>
<title>Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-provides-regulatory-deramiocel-141500870</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-provides-regulatory-deramiocel-141500870</guid>
<pubDate>Tue, 20 Jan 2026 14:15:00 GMT</pubDate>
<description>FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today provided a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the Compan</description>
</item>
<item>
<title>Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-parent-project-muscular-210500536</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-parent-project-muscular-210500536</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatm</description>
</item>
<item>
<title>Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-pricing-150-111500621</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-pricing-150-111500621</guid>
<pubDate>Fri, 05 Dec 2025 11:15:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting di</description>
</item>
<item>
<title>Capricor Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-proposed-public-210100769</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-proposed-public-210100769</guid>
<pubDate>Thu, 04 Dec 2025 21:01:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public</description>
</item>
<item>
<title>Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-positive-topline-122000529</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-positive-topline-122000529</guid>
<pubDate>Wed, 03 Dec 2025 12:20:00 GMT</pubDate>
<description>Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat</description>
</item>
<item>
<title>Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-presents-data-demonstrating-140000457</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-presents-data-demonstrating-140000457</guid>
<pubDate>Mon, 24 Nov 2025 14:00:00 GMT</pubDate>
<description>--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamidate morpholino oligomer</description>
</item>
<item>
<title>Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-third-quarter-210100779</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-third-quarter-210100779</guid>
<pubDate>Mon, 10 Nov 2025 21:01:00 GMT</pubDate>
<description>Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with Stealth</description>
</item>
<item>
<title>Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-publishes-peer-reviewed-141500593</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-publishes-peer-reviewed-141500593</guid>
<pubDate>Mon, 03 Nov 2025 14:15:00 GMT</pubDate>
<description>–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro potency assay designed to cha</description>
</item>
<item>
<title>Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-present-third-quarter-131500880</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-present-third-quarter-131500880</guid>
<pubDate>Fri, 31 Oct 2025 13:15:00 GMT</pubDate>
<description>Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p.</description>
</item>
<item>
<title>Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-provides-regulatory-deramiocel-111500730</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-provides-regulatory-deramiocel-111500730</guid>
<pubDate>Thu, 25 Sep 2025 11:15:00 GMT</pubDate>
<description>FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory</description>
</item>
<item>
<title>Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-responds-fda-posting-132000419</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-responds-fda-posting-132000419</guid>
<pubDate>Tue, 09 Sep 2025 13:20:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration’s (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dyst</description>
</item>
<item>
<title>Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-first-subjects-130000142</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-announces-first-subjects-130000142</guid>
<pubDate>Mon, 18 Aug 2025 13:00:00 GMT</pubDate>
<description>First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vac</description>
</item>
<item>
<title>Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-second-quarter-200500526</link>
<guid isPermaLink="true">https://6ix.com/company/capricor-therapeutics-inc/news/capricor-therapeutics-reports-second-quarter-200500526</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balan</description>
</item>
</channel>
</rss>